Alexandr Ishkin, PhD
Principal Consultant for Discovery and Translational Science Consulting
Alex has over 15 years of experience as a science analyst in systems biology and bioinformatics, working with GeneGo and later Thomson Reuters and Clarivate. His key expertise is in network and pathway analysis of high-throughput molecular data sets, such as DNA-Seq, RNA-Seq, single-cell RNA-Seq, gene expression microarray, proteomics and metabolomics, in the context of drug development.
Alex is an expert in Clarivate’s products MetaBaseTM and CDDI. For over 10 years, he has been responsible for development and maintenance of Clarivate’s metabaseR package that enables efficient access to and bioinformatics analyses of the extensive MetaBaseTM content.
Alex is a program manager and principal software developer for two Clarivate-led precompetitive consortia, CBDD and ABC. The CBDD consortium (Computational Biology for Drug Discovery) was launched in 2013. Within the consortium, Alex developed a toolkit of over 70 advanced network analysis algorithms for drug discovery. Consortium members include Novartis, Pfizer, Sanofi, Roche, Merck, Janssen, Takeda, Boehringer Ingelheim, Eli Lilly, BMS, Abbvie, Biogen, UCB, Regeneron, and Daiichi Sankyo. The ABC (Algorithm Benchmarking Consortium) program is centered around benchmarking bioinformatics tools relevant for drug development research and has been running since 2021. Since its inception, the program helped customers to identify best-performing tools and practices across many areas of bioinformatics research.
Latest news
Clarivate Launches DRG Commercial Analytics 360 Enabling Medtech Companies to Advance Commercial Strategy and Execution
New solution provides integrated provider intelligence and real-world data to optimize targeting, strategic planning and patient access across commercial organizations London, U.K. April 23, 2025: Clarivate Plc (NYSE:CLVT), a leading…
